Somatropin - Omnitrope (Sandoz) - Complete Research Paper

1. Summary

Omnitrope is a recombinant human growth hormone (rhGH, somatropin) manufactured by Sandoz (a Novartis division). It holds the distinction of being the first "follow-on protein" (biosimilar-equivalent) approved by the FDA, having received approval on May 30, 2006. While approved before the formal biosimilar pathway was established, Omnitrope is substantially similar to the reference product Genotropin (Pfizer) and is approved for identical indications.

FDA Approval: May 30, 2006 (Initial); subsequent indication expansions through 2011 Manufacturer: Sandoz Biopharmaceuticals (Novartis division) Reference Product: Genotropin (Pfizer)

Regulatory Milestone: Omnitrope was the first follow-on biologic approved in the EU, Japan, Canada, Taiwan, Australia, and the United States. This pioneering status makes it a historically significant product in the development of biosimilar regulation globally.

Key Clinical Features:

• Drug class: Recombinant human growth hormone (somatropin)
• Molecular weight: ~22,125 daltons (191 amino acids)
• Administration: Subcutaneous injection
• Half-life: 2.5-2.8 hours (SC)
• Tmax: 4.0 hours
• Bioequivalent to: Genotropin
• Cost advantage: Lower cost than originator brands

Primary Advantage: Omnitrope offers a cost-effective alternative to originator somatropin products while maintaining therapeutic equivalence. It is approved for all the same indications as Genotropin, making it available to more than 90% of patients eligible for human growth hormone treatment in the US.

2. Mechanism of Action

Omnitrope functions identically to natural pituitary-derived human growth hormone and reference products.

Primary Mechanism:

1. GH Receptor Binding: Somatropin binds to GHR on target cells
2. Receptor Activation: JAK2-STAT5 signaling pathway activation
3. Gene Transcription: Growth-related gene expression
4. IGF-I Synthesis: Hepatic IGF-I production stimulated

Direct Effects:

• Skeletal growth at epiphyseal plates
• Muscle protein synthesis
• Bone metabolism enhancement
• Organ growth stimulation

Metabolic Effects: | System | Effect | |---

Goal Relevance:

• Increase height in children with growth hormone deficiency or idiopathic short stature
• Support muscle growth and strength in individuals with growth hormone deficiency
• Improve body composition by reducing fat mass and enhancing lean muscle mass
• Aid in recovery and healing for children born small for gestational age
• Enhance bone density and growth in individuals with Turner syndrome
• Support overall growth and development in children with Prader-Willi syndrome
• Provide hormone replacement therapy for adults with growth hormone deficiency to boost energy and vitality

-----|--------| | Protein | Increased synthesis, nitrogen retention | | Lipid | Enhanced lipolysis, reduced fat mass | | Carbohydrate | Insulin resistance (dose-dependent) | | Mineral | Increased calcium absorption |

Therapeutic Equivalence: Clinical studies confirm Omnitrope is therapeutically equivalent to Genotropin:

• Same mechanism of action
• Same pharmacokinetic profile
• Same efficacy outcomes
• Same safety profile

3. FDA-Approved Indications

Complete Indication Match with Genotropin: With the 2011 Turner syndrome approval, Omnitrope achieved approval for all indications covered by reference product Genotropin.

Pediatric Indications:

Adult Indication:

Approval Pathway: Omnitrope was approved under Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act. This pathway allowed Sandoz to rely in part on FDA's previous findings of safety and efficacy for the reference product while demonstrating comparability.

4. Dosing and Administration

General Principles:

• Individualize dosage based on growth response
• Divide weekly dose into 6-7 daily injections
• Administer subcutaneously
• Rotate injection sites

Pediatric Dosing by Indication:

Adult GHD Dosing:

Weight-Based:

• Starting: 0.04 mg/kg/week
• Maximum: 0.08 mg/kg/week

Non-Weight-Based (Preferred):

• Starting: 0.2 mg/day (0.15-0.30 mg/day)
• Increase by 0.1-0.2 mg/day every 1-2 months
• Adjust based on clinical response, IGF-I, adverse effects

Product Presentations:

Bioequivalence: The aqueous cartridge formulations are bioequivalent to the lyophilized 5.8 mg/vial formulation.

5. Pharmacokinetics

Absorption:

• Route: Subcutaneous injection
• Bioavailability: Similar to reference product (~70-80%)
• Tmax: 4.0 hours
• Cmax: 72-74 mcg/L (after 5 mg dose in healthy adults)

Distribution:

• Distributes to liver, kidney, muscle, bone, target tissues
• Similar pharmacokinetics in pediatric and adult patients

Metabolism:

• Liver and kidney (proteolytic degradation)
• Classical protein catabolism
• No CYP450 involvement

Elimination:

• Terminal half-life (SC): 2.5-2.8 hours
• Shorter than some other somatropin products (reflects formulation/measurement differences)

Bioequivalence Data: Omnitrope has demonstrated bioequivalence to Genotropin in comparative pharmacokinetic studies.

6. Side Effects and Adverse Reactions

Common Adverse Events: (Similar to reference product Genotropin)

Adults with GHD:

• Peripheral edema
• Arthralgia
• Myalgia
• Paresthesia
• Carpal tunnel syndrome
• Headache

Pediatric Patients:

• Injection site reactions
• Headache
• Hypothyroidism
• Hyperglycemia

Serious Adverse Reactions:

Pediatric-Specific:

• Slipped capital femoral epiphysis
• Benign intracranial hypertension
• Progression of scoliosis
• Pancreatitis (rare)

PWS Patients: Sudden death risk with severe obesity, sleep apnea, or respiratory impairment.

7. Drug Interactions

Same interaction profile as other somatropin products:

• Glucocorticoids: May attenuate growth effects
• Thyroid hormones: May unmask hypothyroidism
• Insulin/antidiabetics: May require adjustment
• Oral estrogen: May reduce IGF-I response
• CYP450 substrates: Potential metabolism effects

8. Contraindications

Absolute Contraindications:

1. Acute critical illness
2. Active malignancy
3. Closed epiphyses (for growth indications)
4. PWS with severe obesity/respiratory impairment
5. Hypersensitivity to somatropin or excipients
6. Active diabetic retinopathy

9. Special Populations

Pediatric: Safety and efficacy established for approved indications

Geriatric: Limited data; use lower doses, monitor closely

Pregnancy: Use only if clearly needed

Lactation: Caution advised

Renal/Hepatic Impairment: Use with caution; reduced clearance expected

10. Monitoring Parameters

Standard somatropin monitoring applies:

Baseline: Height/weight, bone age, IGF-I, thyroid function, glucose/HbA1c, fundoscopic exam

Ongoing:

• Height velocity (every 3-6 months, pediatric)
• IGF-I (after dose changes; every 6-12 months)
• Thyroid function (every 6-12 months)
• Glucose (every 6-12 months)
• Hip/knee exam for SCFE (each visit, pediatric)

11. Cost and Availability

Pricing (United States, 2024-2025):

Cost Advantage: Omnitrope's primary differentiation is its lower cost compared to originator products like Genotropin, Humatrope, and Norditropin.

Patient Assistance Programs:

Omnitrope Co-Pay Savings Program:

Self-Pay/Cash Patients:

• Save up to $417 per 30-day supply
• Available for uninsured and uncovered patients

OmniSource Patient Support:

• Comprehensive support program
• Co-pay assistance
• Self-pay program
• Reimbursement support

Novartis Patient Assistance:

• Free medication for eligible patients
• Income-based eligibility

12. Clinical Evidence Summary

PATRO Studies: Real-world evidence studies (PATRO Children, PATRO Adults) have demonstrated:

• Efficacy comparable to reference products
• Safety profile consistent with expectations
• Long-term data supporting use

Bioequivalence: Comparative PK studies confirm therapeutic equivalence to Genotropin.

Growth Outcomes: Height velocity improvements comparable to originator products across all approved indications.

13. Comparison with Alternatives

When to Choose Omnitrope:

1. Cost-conscious patients/payers
2. Insurance formulary preference
3. Equivalent efficacy desired at lower price
4. Patient comfortable with pen or vial options

14. Storage and Handling

Before Reconstitution (Vials):

• Refrigerate 2-8°C (36-46°F)
• Do not freeze

Cartridges:

• Refrigerate 2-8°C before use
• After first use: Refrigerate; use within 28 days
• Do not freeze

Reconstituted Vials:

• Refrigerate
• Use within 3 weeks

15. References

1. Omnitrope Prescribing Information. Sandoz. 2024. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/021426s043lbl.pdf

2. FDA Drug Approval Package: Omnitrope NDA #021426. 2006. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021426s000TOC.cfm

3. Drugs.com. Omnitrope (somatropin) FDA Approval History. Available at: https://www.drugs.com/history/omnitrope.html

4. Current Status of Biosimilar Growth Hormone. PMC. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC2777019/

5. DailyMed. OMNITROPE- somatropin injection. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=58d84ffa-4056-4e36-ad67-7bd4aef444a5

6. GoodRx. Omnitrope 2025 Prices, Coupons & Savings Tips. Available at: https://www.goodrx.com/omnitrope

7. Omnitrope Official Site - Patient Support. Available at: https://www.omnitrope.com/patient-support-program/

8. Healthline. Omnitrope and Cost: Ways to Save. Available at: https://www.healthline.com/health/drugs/omnitrope-cost

9. Sandoz Biosimilars Portfolio. Available at: https://www.sandoz.com/business/biosimilars/our-biosimilars/

10. RxList. Omnitrope (Somatropin): Side Effects, Uses, Dosage. Available at: https://www.rxlist.com/omnitrope-drug.htm

Document compiled from FDA prescribing information, manufacturer resources, and clinical literature. Last updated: December 2024.

Status: PAPER 71 OF 76 COMPLETE

Next Paper: #72 - Somatropin (Saizen)